A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-Aβ protofibril antibody.

Alzheimers Res Ther · 2021 · PMC8053280 · PMID 33865446

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

nominally significantno p-value reported

The 10 mg/kg biweekly group, despite being limited in size and ApoE4+ balance, showed nominally significant differences versus placebo on ADCOMS and ADAS-Cog14 at 18 months of treatment.

also in 7,732 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.